Search Results 21-30 of 21237 for Inhibition

  1. Development of PARP Inhibitors and DDR Modifiers To Treat Ovarian Cancer - Anticancer Drug Action Laboratory - Mayo Clinic Research

    Demonstration that PARP inhibitors sensitize ovarian cancer cells with either wild type or mutant BRCA1/BRCA2 proteins to the topoisomerase I poison topotecan ...

  2. Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction - Mayo Clinic

    To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin ( ...

  3. A Study of How Age Affects Osteoclast Inhibition and Bone Formation - Mayo Clinic

    This protocol addresses three main questions. How are gene expression changes in bone cells affected by aging? Is aging associated with decreased signaling ...

  4. Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma - Mayo Clinic

    About this study. To evaluate the preliminary efficacy of the established dose of indoximod in combination with immune checkpoint inhibition as measured by ...

  5. Anti-inhibitor coagulant complex (intravenous route) - Side effects & uses - Mayo Clinic

    Description. Anti-inhibitor coagulant complex injection is used to treat, control, prevent, and decrease bleeding episodes or frequency of bleeding during ...

  6. Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial - Mayo Clinic

    A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute ...

  7. Targeting Matrix Metalloproteinases Using Tissue Inhibitors - Proteases in Cancer Laboratory - Mayo Clinic Research

    The Proteases in Cancer Lab of Evette S. Radisky, Ph.D., at Mayo Clinic is developing inhibitors for several MMPs known to promote cancer progression by ...

  8. Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk - Mayo Clinic

    About this study. The primary hypothesis is that additional LDL-C lowering with Evolocumab (AMG 145) when used in addition to other treatment for ...

  9. Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function - Mayo Clinic

    Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal ...

  10. ACE Inhibitors - Mayo Clinic News Network

    Or, a physician may recommend an ACE inhibitor with other types of blood pressure-lowering medications such as a diuretic or calcium channel blocker. ACE ...